Standout Papers

Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia 2022 2026 2023 2024115
  1. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia (2022)
    Naval Daver, Alexander E. Perl et al. Journal of Clinical Oncology

Immediate Impact

11 from Science/Nature 60 standout
Sub-graph 1 of 23

Citing Papers

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
Bioengineering in Solid-State Fermentation for next sustainable food bioprocessing
2025 Standout
2 intermediate papers

Works of James McCloskey being referenced

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
2020
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia
2017

Author Peers

Author Last Decade Papers Cites
James McCloskey 472 161 148 353 162 63 760
Shira Dinner 358 153 141 302 213 67 693
Marie‐Christiane Vekemans 441 160 203 251 191 40 811
Chezi Ganzel 600 174 161 275 210 66 870
Rita Assi 375 134 162 224 228 49 790
Martine Delain 548 129 235 203 260 35 872
C. Michel Zwaan 299 138 181 281 262 73 891
Akio Kohno 350 134 107 199 254 61 750
G. Prindull 316 151 166 268 165 82 853
Bhavana Bhatnagar 427 121 154 381 292 79 847
Charlotte Guldborg Nyvold 522 180 284 358 158 73 956

All Works

Loading papers...

Rankless by CCL
2026